Glycogen storage disease type II
Medical condition / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Glycogen storage disease type II?
Summarize this article for a 10 year old
Glycogen storage disease type II (GSD-II), also called Pompe disease, and formerly known as GSD-IIa or Limb–girdle muscular dystrophy2V, is an autosomal recessive metabolic disorder[1] which damages muscle and nerve cells throughout the body. It is caused by an accumulation of glycogen in the lysosome due to deficiency of the lysosomal acid alpha-glucosidase enzyme (GAA). The inability to breakdown glycogen within the lysosomes of cells leads to progressive muscle weakness throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver and the nervous system.
This article includes a list of general references, but it lacks sufficient corresponding inline citations. (January 2021) |
This article needs more reliable medical references for verification or relies too heavily on primary sources. (February 2023) |
Pompe disease (Glycogen storage disease type II) | |
---|---|
Other names | Pompe disease; acid maltase deficiency; GSD-IIa; LGMD2V |
Muscle biopsy showing large vacuoles in a case of Pompe disease (HE stain, frozen section) | |
Pronunciation |
|
Specialty | Endocrinology |
GSD-II and Danon disease are the only glycogen storage diseases characterised by a defect in lysosomal metabolism. It was first identified in 1932 by Dutch pathologist Joannes Cassianus Pompe, making it the first glycogen storage disease to be discovered.